Core Viewpoint - OneMedNet Corporation is advancing its commercial launch of the RWD Platform powered by Palantir Foundry, converting customer evaluations into subscriptions and reinforcing its position in the life sciences and healthcare sectors [1][4]. Group 1: Commercial Launch and Subscription Growth - The launch is driving rapid expansion of subscription contracts, including multi-year deals that represent millions in incremental recurring revenue [2]. - The OneMedNet iRWD™ network has over 2,130 healthcare sites, and as it scales, the subscription value increases due to greater scale, diversity, real-time access, and analytical depth [2][4]. Group 2: Customer Feedback and Platform Strengths - Customer feedback confirms the platform's strengths, including unmatched analytical depth, accelerated cohort feasibility, streamlined workflows, and faster onboarding of data partners [3]. - The platform provides near real-time access to comprehensive regulatory-grade multimodal RWD, enhancing study design and evidence generation [5][6]. Group 3: Investor Benefits - The commercial launch supports OneMedNet's high-margin recurring revenue model, with evaluation conversions to multi-year subscriptions expected to drive predictable growth and millions in incremental annual recurring revenue [4]. - Network expansion is anticipated to boost deal sizes and penetration in life sciences, AI, and research sectors, fueling sustained bookings [4]. Group 4: Company Overview and Industry Impact - OneMedNet is revolutionizing access to Real-World Data (RWD) through its iRWD™ platform, which harnesses data from over 2,130 healthcare sites, impacting drugmakers, medical device innovators, and AI developers [8]. - The company's proprietary AI also anonymizes data for other industries, such as finance and retail, enhancing project de-risking and secure data sharing [9].

Core Insights - OneMedNet Corporation has announced a strategic partnership with ViuHealth to enhance its Real-World Data (RWD) offerings, particularly in the autoimmune disease sector [1][2] Group 1: Partnership Details - The partnership will integrate ViuHealth's longitudinal autoimmune disease data into OneMedNet's iRWD™ platform, which is powered by Palantir Foundry, thereby increasing the scale and diversity of regulatory-grade RWD [2][6] - ViuHealth will provide ongoing data that captures patient journeys, treatment adherence, flares, and outcomes, which will support pharmaceutical partners in drug discovery and market strategies [3][4] Group 2: Market Opportunity - The autoimmune therapeutics market is projected to exceed $166 billion globally in 2026, indicating a significant opportunity for pharmaceutical and biotechnology companies to leverage the enriched datasets for drug development and regulatory evidence [3][14] - Autoimmune diseases affect approximately 8% of the U.S. population, representing tens of millions of individuals, creating strong demand for longitudinal real-world data in life sciences and digital health [5][14] Group 3: Revenue Growth Strategy - This partnership is expected to drive OneMedNet's subscription revenue growth by integrating high-value, disease-specific data into the iRWD™ platform, making it more attractive for ongoing subscriptions rather than one-time sales [4][14] - The collaboration aims to create predictable Annual Recurring Revenue (ARR) and enhance customer retention through expanded data feeds [14] Group 4: Company Positioning - OneMedNet is positioning itself as a trusted data infrastructure provider in specialty disease areas, reinforcing its role in the rapidly growing real-world data and AI-enabled healthcare markets [7][8] - The company aims to build repeatable, subscription-oriented data partnerships that generate continuous data flows, enhancing its ability to deliver relevant cohorts reflecting real-world patient journeys [7][14]